eligibility_summary
Adults ≥18 with confirmed metastatic or unresectable platinum‑resistant ovarian, NSCLC, PDAC, endometrial, colorectal, or mesothelioma, post standard therapy/no options. ECOG 0–1, measurable disease (RECIST v1.1), archival/fresh tumor tissue, adequate hepatic/renal/bone marrow, ≤2 prior cytotoxic lines in metastatic setting (Parts B/C). Exclude recent therapy/radiation, prior anti‑MSLN/ADC (Part C), >G1 toxicities, organ/blood issues, untreated brain mets (treated ≥4 wks, stable, off steroids ok).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06466187 (Phase 1). Intervention: SGN-MesoC2 (PF-08052666, HBM9033), an antibody-drug conjugate (ADC) given IV as monotherapy. Mechanism: a monoclonal antibody binds mesothelin (MSLN) on tumor cells, is internalized, and releases an attached cytotoxic payload inside the cell to induce tumor cell death, may also affect normal MSLN-expressing cells. Study design: dose escalation/optimization (Parts A/B) followed by dose expansion (Part C) to assess safety, PK, and antitumor activity. Targets: mesothelin-expressing solid tumors, including ovarian (platinum-resistant), NSCLC, pancreatic ductal adenocarcinoma, colorectal, endometrial cancers, and mesothelioma. Biology/pathway focus: MSLN cell-surface antigen on tumor cells, mechanism relies on antigen-directed delivery and intracellular toxin release (with potential bystander effect).